Innate Pharma (IPHYF) Operating Margin (2019 - 2025)
Historic Operating Margin for Innate Pharma (IPHYF) over the last 7 years, with Q2 2025 value amounting to 907.14%.
- Innate Pharma's Operating Margin fell 5898400.0% to 907.14% in Q2 2025 from the same period last year, while for Jun 2025 it was 145.06%, marking a year-over-year decrease of 1448700.0%. This contributed to the annual value of 256.32% for FY2024, which is 2357700.0% down from last year.
- Per Innate Pharma's latest filing, its Operating Margin stood at 907.14% for Q2 2025, which was down 5898400.0% from 391.94% recorded in Q4 2024.
- In the past 5 years, Innate Pharma's Operating Margin registered a high of 0.12% during Q4 2022, and its lowest value of 907.14% during Q2 2025.
- Over the past 5 years, Innate Pharma's median Operating Margin value was 317.29% (recorded in 2024), while the average stood at 286.81%.
- Per our database at Business Quant, Innate Pharma's Operating Margin skyrocketed by 3753600bps in 2022 and then crashed by -5898400bps in 2025.
- Over the past 5 years, Innate Pharma's Operating Margin (Quarter) stood at 375.48% in 2021, then soared by 100bps to 0.12% in 2022, then crashed by -12374bps to 14.59% in 2023, then crashed by -2587bps to 391.94% in 2024, then plummeted by -131bps to 907.14% in 2025.
- Its Operating Margin was 907.14% in Q2 2025, compared to 391.94% in Q4 2024 and 317.29% in Q2 2024.